Partners News Radboudumc and Terumo Europe NV sign collaboration agreement

3 June 2022

Radboudumc and Terumo Europe N.V. signed a strategic collaboration agreement. Together, the two partners will improve existing treatments for cancer patients and develop new, personalized therapies. Focus will be on the clinical use of holmium-166 microspheres, small radioactive beads.

Holmium-166 microspheres are currently used in the image-guided irradiation of liver tumors from the inside. This technique is also called radioembolization or selective internal radiation therapy (SIRT). Using a catheter, millions of radioactive beads, or microspheres, are injected into a patient's hepatic artery. The radioactive microsphere then lodge in blood vessels in and around the targeted tumor(s), irradiating the tumor cells at close range.

Personalized treatment

The biggest challenge with radioembolization is getting the right number of microspheres to the right places in the body to reach the correct dose to the tumor. "The Radboudumc is ideally placed to investigate this further," says Jurgen Fütterer, interventional radiologist at Radboudumc. "In our MITeC operating rooms, we can follow the microspheres live on the MRI during treatment. This way we learn to control them better and we can also adjust the dosage on the spot to the individual patient."

The holmium-166 microspheres are supplied by Deventer-based Quirem Medical, a Terumo Europe N.V. company. Quirem Medical and Radboudumc have been collaborating on radioembolization for several years.  With the new collaboration agreement, Terumo is intensifying its research collaboration with Radboudumc.

"With the recent creation of the Global Therapeutic Interventional Oncology team, Terumo Europe N.V. aims at developing improved cancer care. In that effort, this collaboration with Radboudumc is an essential milestone and we look forward to an accelerated innovation for the benefit of patients. " said Laurent Domas, Vice-President Global Interventional Oncology Strategy and Therapy Development at Terumo.

New applications for out-of-treatment patients

Radioembolization is now mainly used in patients with primary or secondary liver cancer, for whom surgery is no longer an option. Radioembolization helps to extend the lives of these patients. Radboudumc and Terumo Europe N.V. hope to be able to offer them more perspectives in the future with this image-guided and personalized treatment.

"Our approach is unique; the image-guided and custom-dosed administration of the holmium microspheres has not yet been done anywhere in the world," says Frank Nijsen, associate professor at Radboudumc and group leader of the radioembolization study. "Together with Terumo Europe N.V., we will further refine this technique. Our research focuses on patients with conditions that are currently not or barely treatable: metastatic liver cancer, but also brain cancer and pancreatic cancer."

"We are delighted with the confidence Terumo has expressed in our research and facilities," said Jan Smit, member of the Board of Directors at Radboudumc. "Terumo's expertise and input also help tremendously in accelerating and translating our research into concretely applicable therapies. Hopefully, this will ultimately benefit cancer patients around the world."

About Terumo Europe NV

Terumo Europe N.V. is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets, and sells a vast range of medical devices in five main business units: Interventional Systems, Pharmaceutical Solutions, Medical Products, Cardiovascular Products and Diabetes Management. Terumo Europe EMEA headquarters and production facilities are located in Leuven (Belgium), production facility in Knowsley (UK), European Distribution Center in Genk (Belgium) and sales offices across EMEA.

Terumo Europe's website

About Radboudumc

Radboudumc wants to lead the way in the development of innovative, sustainable and affordable healthcare and has the mission: 'to make a significant impact on healthcare'.

Related news items


Joining forces increases innovation Janssen and Radboud

1 December 2022

Dr. Eng Kinga Matuła (KM), specialist in single-cell multi-omics and Jeroen Van Houdt (JH), Omics group leader at Janssen Pharmaceutica, answer three pressing questions about the successful collaboration in the single-cell technology project.

read more

Enzyre closes Series A financing round of €12M to advance pioneering diagnostic technology platform for hemophilia patients

2 November 2022

Enzyre has announced that it has successfully raised €12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment, Takeda Ventures, and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government.

read more

Successful matchmaking at Radboudumc Investment Day  

7 October 2022

On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.

read more

SPL Medical announces collaboration with NanoEcho for application of Ferrotran® (Ferumoxtran) for Ultrasound detection of Lymph node metastases

30 September 2022

SPL medical and NanoEcho have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for SPL medical proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform.

read more

Radboudumc Investment Day 2022

26 September 2022

Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!

read more

More accurate surgery with the Anatomy Projector

30 May 2022 The Anatomy Projector, developed at the Radboudumc, allows surgeons to operate much more accurately with projected augmented reality. read more